M
M. van Glabbeke
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 140
Citations - 12023
M. van Glabbeke is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Soft tissue sarcoma & Chemotherapy. The author has an hindex of 50, co-authored 140 publications receiving 11261 citations.
Papers
More filters
Journal ArticleDOI
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
Jacques Bernier,Jay S. Cooper,Thomas F. Pajak,M. van Glabbeke,Jean Bourhis,Arlene A. Forastiere,Esat Mahmut Ozsahin,John R. Jacobs,Jacek Jassem,K. Kian Ang,J.L. Lefebvre +10 more
TL;DR: Level I evidence was established for the postoperative adjuvant treatment of patients with selected high‐risk locally advanced head and neck cancers, with the publication of the results of two trials conducted in Europe and the United States.
Journal ArticleDOI
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
Harry Bartelink,F. Roelofsen,François Eschwege,Ph. Rougier,J.F. Bosset,Dionisio González González,Didier Peiffert,M. van Glabbeke,Marianne Pierart +8 more
TL;DR: The concomitant use of radiotherapy and chemotherapy resulted in a significantly improved locoregional control rate and a reduction of the need for colostomy in patients with locally advanced anal cancer without a significant increase in late side effects.
Journal ArticleDOI
Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy.
Jean-Claude Horiot,R. Le Fur,T. N'Guyen,C. Chenal,S. Schraub,S. Alfonsi,Gianstefano Gardani,W. Van den Bogaert,S. Danczak,M. Bolla,M. van Glabbeke,M. de Pauw +11 more
TL;DR: EORTC protocol 22791 compared once daily fractionation (CF) to pure hyperfractionation (HF) of 80.5 Gy in 70 fractions in 7 weeks using 2 fractions of 1.15 Gy per day in T2-T3 oropharyngeal carcinoma (excluding base of tongue), N0,N1 of less than 3 cm.
Journal ArticleDOI
A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844
A.B.M.F. Karim,B. Maat,R. Hatlevoll,Johan Menten,Ewald H. J. M. Rutten,D.G.T. Thomas,F. Mascarenhas,Jean-Claude Horiot,L.M. Parvinen,M. van Reijn,Jos J. Jager,M.G. Fabrini,A.M. van Alphen,H.P. Hamers,L. Gaspar,E. Noordman,Marianne Pierart,M. van Glabbeke +17 more
TL;DR: The EORTC trial 22844 has not revealed the presence of radiotherapeutic dose-response for patients with LGG for the two dose levels investigated with this conventional setup, but objective prognostic parameters are recognized.
Journal ArticleDOI
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
M. van Glabbeke,A. van Oosterom,J.W. Oosterhuis,Henning T. Mouridsen,Derek Crowther,Riet Somers,Jaap Verweij,Armando Santoro,J. Buesa,Thomas Tursz +9 more
TL;DR: It is demonstrated that for advanced soft tissue sarcoma, response to chemotherapy is not predicted by the same factors as is overall survival time and needs to be taken into account in the interpretation of trials assessing the value of new agents for this disease on the basis of response to treatment.